2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3691
    CART (1-39), Human 99.79%
    CART (1-39), Human, Rat is a neuropeptide consisting of 1-39 residues of the CART peptide. CART (1-39), Human, Rat is a rat satiety factor with potent appetite-suppressing activity and is closely associated with leptin and neuropeptide Y. CART (1-39), Human, Rat inhibits both normal and starvation-induced feeding. CART (1-39), Human, Rat can induce anxiety and stress-related behavior.
    CART (1-39), Human
  • HY-P3709
    TRAF6 peptide 852805-92-6 98%
    TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke.
    TRAF6 peptide
  • HY-P3785
    PKI(5-22)amide 100853-58-5 98%
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors.
    PKI(5-22)amide
  • HY-P3819
    Delta (Phospho) Sleep Inducing Peptide 70754-23-3 99.01%
    Delta (Phospho) Sleep Inducing Peptide (DSIP-P) is a long-lasting sleep-promoting peptide. Delta (Phospho) Sleep Inducing Peptide induces changes in the circadian locomotor behavior in rats.
    Delta (Phospho) Sleep Inducing Peptide
  • HY-P3844
    Biotinyl-neuropeptide W-23 (human) 1815618-09-7 98.37%
    Biotinyl-neuropeptide W-23 (human) is a biotinylated Neuropeptide W-23 (human) (HY-P1035). Neuropeptide W-23 (human) is an agonist of NPBW1 (GPR7) and NPBW2 (GPR8).
    Biotinyl-neuropeptide W-23 (human)
  • HY-P3851
    (β-Ala8)-Neurokinin A (4-10) 127633-71-0 98%
    (β-Ala8)-Neurokinin A (4-10), a neuropeptide, is a potent and selective NK-2 tachykinin receptor (Neurokinin Receptor) agonist.
    (β-Ala8)-Neurokinin A (4-10)
  • HY-P3882
    Fmoc-Ala-Glu-Gln-Lys-NH2 99.90%
    Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein.
    Fmoc-Ala-Glu-Gln-Lys-NH2
  • HY-P3888
    Gly-Leu-Met-NH2 4652-64-6 99.76%
    Gly-Leu-Met-NH2 is a C-terminal tripeptide of Substance P (HY-P0201). Substance P is a neuropeptide.
    Gly-Leu-Met-NH2
  • HY-P3925
    [His11]Substance P 98.97%
    [His11]Substance P is an analog of Substance P (HY-P0201). Substance P is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS.
    [His11]Substance P
  • HY-P4156
    VLVNTFCDSCIPKTYWNLGY TFA
    VLVNTFCDSCIPKTYWNLGY TFA is an antigenic peptide of M3 muscarinic receptor (M3R). VLVNTFCDSCIPKTYWNLGY TFA can be used in ELISA.
    VLVNTFCDSCIPKTYWNLGY TFA
  • HY-P4439
    H-Met-Val-OH 14486-13-6 99.40%
    H-Met-Val-OH is a dipeptide containing free N-terminal methionine. H-Met-Val-OH exhibits activity against cDNA expressing Flavin-containing monooxygenase (FMO) 1 and FMO3. H-Met-Val-OH has potential applications in the growth of neuritis.
    H-Met-Val-OH
  • HY-P4704
    α-Synuclein (61-95) (human) 154040-19-4 98%
    α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
    α-Synuclein (61-95) (human)
  • HY-P4886
    Amyloid β-Protein (3-42) 157884-74-7 99.20%
    Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42).
    Amyloid β-Protein (3-42)
  • HY-P4895
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin 77327-45-8 99.20%
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease.
    (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin
  • HY-P4933
    Tau Peptide (255-314) (Repeat 2 Domain) (human) 2022995-68-0
    Tau Peptide (255-314) (Repeat 2 Domain) (human) (Tau-F protein (255-314)) is a polypeptide. Tau Peptide (255-314) (human) is the 255-314 fragment of Tau-F (also known as Tau-4, the 2N4 isoform), a major isoform of the Tau protein. Tau Peptide (255-314) (human) contains two core driving sequences for Tau aggregation, namely PHF6* (275-280, VQIINK) and PHF6 (306-311, VQIVYK), and spans the C-terminal half of repeat domain R1, the entire repeat domain R2, and the N-terminal half of repeat domain R3 within the microtubule-binding region (MTBR).
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
  • HY-P4943
    Tau Peptide (273-284) 1663490-91-2 98.81%
    Tau Peptide (273-284) is a Tau fragment. Tau Peptide (273-284) can be used in the research of tauopathies, especially Alzheimer's disease.
    Tau Peptide (273-284)
  • HY-P5096
    FITC-β-Ala-Amyloid β-Protein (1-42) 1802087-77-9 98%
    FITC-β-Ala-Amyloid β-Protein (1-42) is a FITC tagged Aβ1-42 peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease.
    FITC-β-Ala-Amyloid β-Protein (1-42)
  • HY-P5117
    TAT-CIRP 98.32%
    TAT-CIRP is a a small peptide, refers to Trans-trans-activating (Tat)-cold-inducible RNA binding protein. TAT-CIRP is an inhibitor of myeloid differentiation protein 2 (MD2). TAT-CIRP exhibits robust neuroprotection against ischemic and hemorrhagic stroke in mice.
    TAT-CIRP
  • HY-P5184
    Hainantoxin-IV 651782-02-4
    Hainantoxin-IV is a specific antagonist of Sodium Channel, targeting to tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channels. His28 and Lys32 are the key resiudes of Hainantoxin-IV for binding with target, while Hainantoxin-IV adopts an inhibitor cystine knot motif.
    Hainantoxin-IV
  • HY-P5308
    β-Amyloid (1-19) acetate 98%
    β-Amyloid (1-19) (acetate) is the acetate form of β-Amyloid (1-19)，which consists of amino acids 1 to 19 of beta amyloid protein.
    β-Amyloid (1-19) acetate
Cat. No. Product Name / Synonyms Application Reactivity